Role of Complexed PSA in the Early Detection of Prostate Cancer

Prostate cancer is a clinically significant health care problem in the United States. Total prostate specific antigen (tPSA) is widely used to detect prostate cancer with a significant increase in the incidence of organ-confined disease at the time of diagnosis. The limitations of tPSA are low specificity and positive predictive value. Numerous attempts to enhance PSA's performance based on prostate volume, patient age, patient race, and PSA velocity have shown little clinical improvement. Percent free PSA has proven to be somewhat improved but still limited. Recently, the complexed PSA (cPSA) assay was developed and multisite institutional studies have shown that cPSA has improved specificity over tPSA. Complexed PSA can replace tPSA as a first screening test.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Yoshio Naya, MD, PhD, Department of Urology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kyoto, Japan, 602-8566. E-mail: yoshionaya@hotmail.com
  • 1

    Jemal A, Murray T, Samuels A. Cancer statistics, 2003. CA Cancer J Clin 2003;53:526.

  • 2

    Catalona WJ, Smith DS, Ratliff TL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:11561161.

    • Search Google Scholar
    • Export Citation
  • 3

    Babaian RJ, Kojima M, Ramirez EI. Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer. J Urol 1996;156:432437.

    • Search Google Scholar
    • Export Citation
  • 4

    Nalder RB, Humphrey PA, Smith DS. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostatic specific antigen levels. J Urol 1995;154:407413.

    • Search Google Scholar
    • Export Citation
  • 5

    Djavan B, Zlotta AR, Byttebier G. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 1998;160:411418.

    • Search Google Scholar
    • Export Citation
  • 6

    Maeda H, Arai Y, Ishitoya S. Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer. J Urol 1997;158:21932196.

    • Search Google Scholar
    • Export Citation
  • 7

    DeAntoni EP, Crawford ED, Oesterling JE. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology 1996;48:234239.

    • Search Google Scholar
    • Export Citation
  • 8

    Catalona WJ, Partin AW, Slawin KM. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective multicenter clinical trial. JAMA 1998;279:15421547.

    • Search Google Scholar
    • Export Citation
  • 9

    Catalona WJ, Partin AW, Finlay JA. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999;54:220224.

    • Search Google Scholar
    • Export Citation
  • 10

    Djavan B, Zlotta A, Kratzik C. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology 1999;54:517522.

    • Search Google Scholar
    • Export Citation
  • 11

    Jung K, Stephan C, Elgeti U. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 μg/L: Are they useful tools for early detection and screening of prostate cancer? Int J Cancer 2001;93:759765.

    • Search Google Scholar
    • Export Citation
  • 12

    Roehl KA, Antenor JV, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/mL range. J Urol 2002;168:922925.

    • Search Google Scholar
    • Export Citation
  • 13

    Stenman UH, Leinonen J, Alfthan H. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of men with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222226.

    • Search Google Scholar
    • Export Citation
  • 14

    Christensson A, Bjork T, Nilsson O. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100105.

    • Search Google Scholar
    • Export Citation
  • 15

    Lilja H, Christensson A, Dahlen U. Prostate specific antigen (PSA) in human serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 1991;37:16181625.

    • Search Google Scholar
    • Export Citation
  • 16

    Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998;44:12161223.

    • Search Google Scholar
    • Export Citation
  • 17

    Brawer MK, Meyer GE, Letran JL. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998;52:372378.

    • Search Google Scholar
    • Export Citation
  • 18

    Brawer MK, Meyer GE, Letran JL. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000;163:14761480.

    • Search Google Scholar
    • Export Citation
  • 19

    Mitchell ID, Croal BL, Dickie A. A prospective study to evaluate the role of complexed prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol 2001;165:15491553.

    • Search Google Scholar
    • Export Citation
  • 20

    Morris DL, Dillon PW, Very DL. Bayer Immuno 1 PSA Assay: an automated, ultrasensitive method to quantitate total PSA in serum. J Clin Lab Anal 1998;12:6574.

    • Search Google Scholar
    • Export Citation
  • 21

    Okihara K, Ukimura O, Nakamura T. Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men? Eur Urol (in press).

    • Search Google Scholar
    • Export Citation
  • 22

    Ian W, Iraj B, Frank M. Acridinium esters as high-specific-activity labels in immunoassay. Clin Chem 1983;29:14741479.

  • 23

    Okegawa T, Noda H, Nutahara K. Comparison of two investigative assays for the complexed prostate specific-antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL. Urology 2000;55:700704.

    • Search Google Scholar
    • Export Citation
  • 24

    Stamey TA, Yemoto CE. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol 2000;163:119126.

    • Search Google Scholar
    • Export Citation
  • 25

    Okihara K, Cheli CD, Partin AW. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 2002;167:20172024.

    • Search Google Scholar
    • Export Citation
  • 26

    Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:14521455.

    • Search Google Scholar
    • Export Citation
  • 27

    Smith DS, Carvalhal GF, Mager DE. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 1998;160:17341738.

    • Search Google Scholar
    • Export Citation
  • 28

    Babaian RJ, Johnston DA, Naccarato W. The incidence of prostate cancer in screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 2001;165:757760.

    • Search Google Scholar
    • Export Citation
  • 29

    Okihara K, Fristche HA, Ayala A. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/ml. J Urol 2001;165:19301936.

    • Search Google Scholar
    • Export Citation
  • 30

    Horninger W, Cheli CD, Babaian RJ. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 2002;60(Suppl 4a):3135.

    • Search Google Scholar
    • Export Citation
  • 31

    Naya Y, Stamey TA, Cheli CD. Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen? Urology 2002;60(Suppl 4a):3641.

    • Search Google Scholar
    • Export Citation
  • 32

    Partin AW, Brawer MK, Bartch G. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003;170:17871791.

    • Search Google Scholar
    • Export Citation
  • 33

    Djavan B, Remzi M, Zlotta AR. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002;60(Suppl 4a):49.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 416 366 25
PDF Downloads 289 271 14
EPUB Downloads 0 0 0